
|Articles|December 26, 2005
Compounders urge FDA to reject Wyeth petition
Advertisement
The International Academy of Compounding Pharmacy (IACP) has urged the FDA to reject Wyeth's citizen's petition to place restrictions on compounded bioequivalent hormone replacement therapy (BHRT). The petition "does not aim to protect women's health, just Wyeth's wealth," by trying to impose far-ranging restrictions on physicians' ability to prescribe and pharmacists' ability to compound BHRT, contended IACP executive director L. D. King.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Functional Somatic Disorder Doesn’t Explain Quality of Life in Long COVID
2
Updated COVID-19 Vaccines Effectively Protect Against Symptomatic Infection
3
Long-Term Glucose-Lowering Therapy Lowers Cardiovascular Risk in Diabetes
4
Gastrointestinal Effects of GLP-1 Drive Discontinuation for Nondiabetic Adults
5
























